|
gptkbp:instance_of
|
gptkb:CEO
gptkb:drug
|
|
gptkbp:activities
|
inhibits angiotensin-converting enzyme
inhibits ACE enzyme
|
|
gptkbp:affects
|
cardiovascular risk reduction
kidney protection
|
|
gptkbp:approves
|
gptkb:1985
gptkb:FDA
|
|
gptkbp:brand
|
gptkb:Vasotec
Epaned
|
|
gptkbp:class
|
gptkb:CEO
|
|
gptkbp:clinical_trial
|
Phase III
first-line treatment for hypertension
adjunct therapy for heart failure
|
|
gptkbp:contraindication
|
gptkb:sacubitril
gptkb:aliskiren
pregnancy
angioedema history
|
|
gptkbp:discovered_by
|
gptkb:Merck_&_Co.
|
|
gptkbp:dosage_form
|
5-40 mg daily
|
|
gptkbp:excretion
|
kidneys
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
enalapril
|
|
gptkbp:ingredients
|
C20 H28 N2 O5
|
|
gptkbp:interacts_with
|
lithium
diuretics
NSAI Ds
|
|
gptkbp:invention
|
patented
|
|
gptkbp:is_affected_by
|
protects kidney function
|
|
gptkbp:is_atype_of
|
C09 A A02
|
|
gptkbp:is_available_on
|
gptkb:tablet
oral solution
|
|
gptkbp:is_monitored_by
|
renal function
potassium levels
|
|
gptkbp:is_used_for
|
hypertension
heart failure
|
|
gptkbp:manager
|
oral
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:previous_name
|
gptkb:battle
|
|
gptkbp:price
|
varies by country
|
|
gptkbp:release_region
|
gptkb:Australia
gptkb:India
gptkb:UK
gptkb:USA
gptkb:Native_American_tribe
|
|
gptkbp:requires
|
prescription only
|
|
gptkbp:research_focus
|
cardiovascular diseases
chronic kidney disease
diabetes management
|
|
gptkbp:safety_features
|
Category D
|
|
gptkbp:side_effect
|
dizziness
fatigue
nausea
cough
low blood pressure
hyperkalemia
lowers blood pressure
reduces heart workload
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:type_of
|
75847-73-3
|
|
gptkbp:bfsParent
|
gptkb:PARADIGM-HF
gptkb:sacubitril/valsartan
|
|
gptkbp:bfsLayer
|
5
|